Looking specifically at AR-associated gene expression in our treatment-naïve primary prostate cancer samples, our AIPC cohort demonstrates significantly lower expression of AR, FOXA1, TMPRSS2, KLK3, AZGP1, and several other AR-associated genes when compared with the non-AIPC cohort. This evidence concerns the gene AZGP1 and prostate carcinoma.